Enterprise Therapeutics, a spin-out of Sussex University set up to work on therapeutics aimed as respiratory diseases, has secured £1.6m ($2.4m) in a series A backed by Epidarex Capital.
The financing will go into funding drug discovery into the area, and will target diseases such as asthma, cystic fibrosis, and chronic obstructive pulmonary disease. Currently, many therapeutics in respiratory diseases combat the conditions by dilating airways or tackling inflammation. Enterprise will look at modifying key drivers of disease pathology, such…
